Judit Demeter

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma

Umberto Vitolo, Marek Trněný, David Belada et al. · Journal of Clinical Oncology · 2017 · 414 citations

Advanced-stage Dlbcl, Lymphoid Neoplasia, Hematological Malignancy +13

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

Martin Dreyling, Armando Santoro, Luigina Mollica et al. · Journal of Clinical Oncology · 2017 · 386 citations

Immunology, Pathology, Pi3k Inhibitor +17

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

Ruben A. Mesa, Alessandro M. Vannucchi, Adam J. Mead et al. · The Lancet Haematology · 2017 · 300 citations · Full text

Hematological Malignancy, Oncology, Pacritinib Versus +9

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Michael R. Grever, Omar Abdel‐Wahab, Leslie A. Andritsos et al. · Blood · 2016 · 271 citations · Full text